PlainRecalls
FDA Drug Moderate Class II Terminated

Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in (a) 150 mL bottle (NDC 0093-4150-80) (b) 80 mL bottle (NDC 0093-4150-79), Rx Only, Manufactured in Canada By: Teva Canada Limited Toronto, Canada, M1B2K9, Manufactured For: Teva Pharmaceuticals USA, INC. North Wales, PA 19454.

Reported: April 24, 2019 Initiated: April 12, 2019 #D-1205-2019

Product Description

Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in (a) 150 mL bottle (NDC 0093-4150-80) (b) 80 mL bottle (NDC 0093-4150-79), Rx Only, Manufactured in Canada By: Teva Canada Limited Toronto, Canada, M1B2K9, Manufactured For: Teva Pharmaceuticals USA, INC. North Wales, PA 19454.

Reason for Recall

Subpotent Product: assay results for Amoxicillin were below the specification limits.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
171,488 150 mL and 80 mL bottles
Distribution
Nationwide in the USA and Puerto Rico
Location
North Wales, PA

Frequently Asked Questions

What product was recalled?
Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in (a) 150 mL bottle (NDC 0093-4150-80) (b) 80 mL bottle (NDC 0093-4150-79), Rx Only, Manufactured in Canada By: Teva Canada Limited Toronto, Canada, M1B2K9, Manufactured For: Teva Pharmaceuticals USA, INC. North Wales, PA 19454.. Recalled by Teva Pharmaceuticals USA. Units affected: 171,488 150 mL and 80 mL bottles.
Why was this product recalled?
Subpotent Product: assay results for Amoxicillin were below the specification limits.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 24, 2019. Severity: Moderate. Recall number: D-1205-2019.